With the rise of genomics and proteomics, many clinically significant targets have been discovered in human diseases. However, a relatively small proportion of traditional druggable targets exists, and many targets […]
Antibody drug conjugates (ADCs) are multi-domain molecules composed of monoclonal antibodies, linkers and small molecule cytotoxins. ADCs specifically bind target antigens highly expressed on the surface of tumor cells through monoclonal antibodies, enter […]
Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. So far, a total of 15 ADC drugs […]
At the 5th United Nations Environment Assembly (UNEA-5) held in March 2022, 175 countries signed a resolution to end plastic pollution. The aim is to achieve a legally binding international agreement […]
mRNA serves as templates for creating proteins, and the quantity of protein generated from each mRNA molecule is contingent on how the translation apparatus commences or elongates the coding sequence (CDS). Additionally, […]
Breast cancer is the leading cause of death among women worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment […]
Introduction of Oligonucleotides Oligonucleotide-based therapeutics represent a rapidly advancing field in current drug development. According to their therapeutic mechanisms, oligonucleotide drugs can be categorized into antisense oligonucleotides (ASOs), small interfering RNA (siRNA), […]
Using synthetic biology methods allows for the more efficient production of highly complex drug molecules compared to traditional chemical methods, with increased stability and controllability. Many drug components are currently […]
Among the first-generation ADC drugs, traditional chemotherapy drugs such as methotrexate, vinblastine, and doxorubicin were used as cytotoxic payloads. However, due to insufficient cytotoxicity and selectivity against tumor cells, the first-generation […]
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal […]